Helen Waller-Evans, DPhil

Helen Waller-Evans, DPhil

Cardiff University

Disease Areas

Neuroscience, Metabolic, Rare/Orphan


Focus

Treating Lysosomal Storage Disorders, Causes of Widespread Organ Damage


Scholar Profile

2021 Harrington UK Rare Disease Scholar

Lysosomes are organelles containing enzymes that break down many kinds of biomolecules. Lysosomal storage disorders (LSDs) are a group of more than 70 rare genetic diseases caused by defects in lysosomal proteins. Although LSDs have a collective frequency of less than one in 5,000 live births, they are the most common cause of childhood neurodegeneration.

Disease-modifying therapies are available for just 16 LSDs, but even these are not suitable for all patients. LSD therapies in development are mostly gene and enzyme replacement therapies, each targeting just a single one of these disorders.

Dr. Waller-Evans' work takes a different approach, focusing on toxic lysosphingolipids, common to nearly all LSDs. Lysosphingolipids are formed via degradation of accumulated sphingolipids — lipids that play important roles in cell recognition and transduction (when cells convert one signal or stimulus into another).

“Sphingolipids are basically fat with sugars on top,” Dr. Waller-Evans says. “Normally these fats get taken into a part of cells called lysosomes, where enzymes chop up these fats, which the cells reuse to build different fats. In LSDs, there may be a defect that negatively affects that chopping process or makes the lysosome less efficient, and so these fats accumulate and are then converted to more toxic lysosphingolipids by the enzyme acid ceramidase (AC).”

It has recently been shown that in one LSD, Krabbe disease, inhibiting AC activity prevented production of lysosphingolipids, which in turn normalized LSD cells. Dr Waller-Evans and her team have uncovered good reasons to believe that this approach would be effective in at least four other LSDs — and of course, the hope is for efficacy in 66 more.

"There are no rare disease experts in my institute, and so the Harrington rare disease expertise has been invaluable."

Source: Article from 2020-2021 Annual Publication

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.

Necessary

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. These cookies do not store any personal information.

Non-Necessary

We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. It is mandatory to procure user consent prior to running these cookies on your website.

Sign Up

Become a part of our community and receive periodic communications with news and updates, as well as notifications of grant funding opportunities.